Arbutus Biopharma
ABUS
ABUS
114 hedge funds and large institutions have $126M invested in Arbutus Biopharma in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 48 increasing their positions, 30 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
3.58% more ownership
Funds ownership: 31.07% → 34.65% (+3.6%)
10% less funds holding
Funds holding: 126 → 114 (-12)
52% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 23
Holders
114
Holding in Top 10
3
Calls
$3.74M
Puts
$1.77M
Top Buyers
| 1 | +$8.97M | |
| 2 | +$8.08M | |
| 3 | +$4.31M | |
| 4 |
BlackRock
New York
|
+$2.87M |
| 5 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$1.39M |
Top Sellers
| 1 | -$3.86M | |
| 2 | -$2.51M | |
| 3 | -$751K | |
| 4 |
Goldman Sachs
New York
|
-$622K |
| 5 |
Parallax Volatility Advisers
San Francisco,
California
|
-$383K |